KDM4/JMJD2 Histone Demethylase Inhibitors Block Prostate Tumor Growth by Suppressing the Expression of AR and BMYB-Regulated Genes

Lingling Duan, Ganesha Rai, Carlos Roggero, Qing Jun Zhang, Qun Wei, Shi Hong Ma, Yunyun Zhou, John Santoyo, Elisabeth D Martinez, Guanghua Xiao, Ganesh Raj, Ajit Jadhav, Anton Simeonov, David J. Maloney, Jose Rizo-Rey, Jer-Tsong Hsieh, Zhi-Ping Liu

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Summary Histone lysine demethylase KDM4/JMJD2s are overexpressed in many human tumors including prostate cancer (PCa). KDM4s are co-activators of androgen receptor (AR) and are thus potential therapeutic targets. Yet to date few KDM4 inhibitors that have anti-prostate tumor activity in vivo have been developed. Here, we report the anti-tumor growth effect and molecular mechanisms of three novel KDM4 inhibitors (A1, I9, and B3). These inhibitors repressed the transcription of both AR and BMYB-regulated genes. Compound B3 is highly selective for a variety of cancer cell lines including PC3 cells that lack AR. B3 inhibited the in vivo growth of tumors derived from PC3 cells and ex vivo human PCa explants. We identified a novel mechanism by which KDM4B activates the transcription of Polo-like kinase 1 (PLK1). B3 blocked the binding of KDM4B to the PLK1 promoter. Our studies suggest a potential mechanism-based therapeutic strategy for PCa and tumors with elevated KDM4B/PLK1 expression.

Original languageEnglish (US)
Pages (from-to)1185-1196
Number of pages12
JournalChemistry and Biology
Volume22
Issue number9
DOIs
StatePublished - Apr 11 2015

Fingerprint

Histone Demethylases
Androgen Receptors
Tumors
Prostate
Genes
Growth
Transcription
Neoplasms
Prostatic Neoplasms
Cells
Cell Line
Therapeutics
polo-like kinase 1

ASJC Scopus subject areas

  • Biochemistry
  • Drug Discovery
  • Molecular Biology
  • Clinical Biochemistry
  • Molecular Medicine
  • Pharmacology

Cite this

KDM4/JMJD2 Histone Demethylase Inhibitors Block Prostate Tumor Growth by Suppressing the Expression of AR and BMYB-Regulated Genes. / Duan, Lingling; Rai, Ganesha; Roggero, Carlos; Zhang, Qing Jun; Wei, Qun; Ma, Shi Hong; Zhou, Yunyun; Santoyo, John; Martinez, Elisabeth D; Xiao, Guanghua; Raj, Ganesh; Jadhav, Ajit; Simeonov, Anton; Maloney, David J.; Rizo-Rey, Jose; Hsieh, Jer-Tsong; Liu, Zhi-Ping.

In: Chemistry and Biology, Vol. 22, No. 9, 11.04.2015, p. 1185-1196.

Research output: Contribution to journalArticle

Duan, Lingling ; Rai, Ganesha ; Roggero, Carlos ; Zhang, Qing Jun ; Wei, Qun ; Ma, Shi Hong ; Zhou, Yunyun ; Santoyo, John ; Martinez, Elisabeth D ; Xiao, Guanghua ; Raj, Ganesh ; Jadhav, Ajit ; Simeonov, Anton ; Maloney, David J. ; Rizo-Rey, Jose ; Hsieh, Jer-Tsong ; Liu, Zhi-Ping. / KDM4/JMJD2 Histone Demethylase Inhibitors Block Prostate Tumor Growth by Suppressing the Expression of AR and BMYB-Regulated Genes. In: Chemistry and Biology. 2015 ; Vol. 22, No. 9. pp. 1185-1196.
@article{e6eafcf0aa604896be055a34b7e1f00d,
title = "KDM4/JMJD2 Histone Demethylase Inhibitors Block Prostate Tumor Growth by Suppressing the Expression of AR and BMYB-Regulated Genes",
abstract = "Summary Histone lysine demethylase KDM4/JMJD2s are overexpressed in many human tumors including prostate cancer (PCa). KDM4s are co-activators of androgen receptor (AR) and are thus potential therapeutic targets. Yet to date few KDM4 inhibitors that have anti-prostate tumor activity in vivo have been developed. Here, we report the anti-tumor growth effect and molecular mechanisms of three novel KDM4 inhibitors (A1, I9, and B3). These inhibitors repressed the transcription of both AR and BMYB-regulated genes. Compound B3 is highly selective for a variety of cancer cell lines including PC3 cells that lack AR. B3 inhibited the in vivo growth of tumors derived from PC3 cells and ex vivo human PCa explants. We identified a novel mechanism by which KDM4B activates the transcription of Polo-like kinase 1 (PLK1). B3 blocked the binding of KDM4B to the PLK1 promoter. Our studies suggest a potential mechanism-based therapeutic strategy for PCa and tumors with elevated KDM4B/PLK1 expression.",
author = "Lingling Duan and Ganesha Rai and Carlos Roggero and Zhang, {Qing Jun} and Qun Wei and Ma, {Shi Hong} and Yunyun Zhou and John Santoyo and Martinez, {Elisabeth D} and Guanghua Xiao and Ganesh Raj and Ajit Jadhav and Anton Simeonov and Maloney, {David J.} and Jose Rizo-Rey and Jer-Tsong Hsieh and Zhi-Ping Liu",
year = "2015",
month = "4",
day = "11",
doi = "10.1016/j.chembiol.2015.08.007",
language = "English (US)",
volume = "22",
pages = "1185--1196",
journal = "Cell Chemical Biology",
issn = "2451-9448",
publisher = "Elsevier Inc.",
number = "9",

}

TY - JOUR

T1 - KDM4/JMJD2 Histone Demethylase Inhibitors Block Prostate Tumor Growth by Suppressing the Expression of AR and BMYB-Regulated Genes

AU - Duan, Lingling

AU - Rai, Ganesha

AU - Roggero, Carlos

AU - Zhang, Qing Jun

AU - Wei, Qun

AU - Ma, Shi Hong

AU - Zhou, Yunyun

AU - Santoyo, John

AU - Martinez, Elisabeth D

AU - Xiao, Guanghua

AU - Raj, Ganesh

AU - Jadhav, Ajit

AU - Simeonov, Anton

AU - Maloney, David J.

AU - Rizo-Rey, Jose

AU - Hsieh, Jer-Tsong

AU - Liu, Zhi-Ping

PY - 2015/4/11

Y1 - 2015/4/11

N2 - Summary Histone lysine demethylase KDM4/JMJD2s are overexpressed in many human tumors including prostate cancer (PCa). KDM4s are co-activators of androgen receptor (AR) and are thus potential therapeutic targets. Yet to date few KDM4 inhibitors that have anti-prostate tumor activity in vivo have been developed. Here, we report the anti-tumor growth effect and molecular mechanisms of three novel KDM4 inhibitors (A1, I9, and B3). These inhibitors repressed the transcription of both AR and BMYB-regulated genes. Compound B3 is highly selective for a variety of cancer cell lines including PC3 cells that lack AR. B3 inhibited the in vivo growth of tumors derived from PC3 cells and ex vivo human PCa explants. We identified a novel mechanism by which KDM4B activates the transcription of Polo-like kinase 1 (PLK1). B3 blocked the binding of KDM4B to the PLK1 promoter. Our studies suggest a potential mechanism-based therapeutic strategy for PCa and tumors with elevated KDM4B/PLK1 expression.

AB - Summary Histone lysine demethylase KDM4/JMJD2s are overexpressed in many human tumors including prostate cancer (PCa). KDM4s are co-activators of androgen receptor (AR) and are thus potential therapeutic targets. Yet to date few KDM4 inhibitors that have anti-prostate tumor activity in vivo have been developed. Here, we report the anti-tumor growth effect and molecular mechanisms of three novel KDM4 inhibitors (A1, I9, and B3). These inhibitors repressed the transcription of both AR and BMYB-regulated genes. Compound B3 is highly selective for a variety of cancer cell lines including PC3 cells that lack AR. B3 inhibited the in vivo growth of tumors derived from PC3 cells and ex vivo human PCa explants. We identified a novel mechanism by which KDM4B activates the transcription of Polo-like kinase 1 (PLK1). B3 blocked the binding of KDM4B to the PLK1 promoter. Our studies suggest a potential mechanism-based therapeutic strategy for PCa and tumors with elevated KDM4B/PLK1 expression.

UR - http://www.scopus.com/inward/record.url?scp=84941935866&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941935866&partnerID=8YFLogxK

U2 - 10.1016/j.chembiol.2015.08.007

DO - 10.1016/j.chembiol.2015.08.007

M3 - Article

VL - 22

SP - 1185

EP - 1196

JO - Cell Chemical Biology

JF - Cell Chemical Biology

SN - 2451-9448

IS - 9

ER -